Rupatadine in Patients With Ulcerative Colitis
Clinical Study to Evaluate Safety and Efficacy of Rupatadine in Patients With Ulcerative Colitis.
Alexandria University
60 participants
Jul 15, 2025
INTERVENTIONAL
Conditions
Summary
Ulcerative colitis (UC) is a chronic inflammatory condition that primarily targets the large intestine. Although substantial progress has been made in treatment modalities-especially with the development of immunomodulatory drugs and biologic therapies-managing UC continues to present significant challenges. At present, there is no definitive cure, and current treatment strategies are largely focused on controlling inflammation, relieving symptoms, and halting disease progression
Eligibility
Inclusion Criteria3
- Age ≥ 18 years
- Both male and female will be included
- Mild and moderate UC patients are already diagnosed and confirmed by endoscope and histopathology.
Exclusion Criteria7
- Breast feeding or pregnancy.
- Colorectal cancer patients.
- Patients with severe UC.
- Patients taking rectal or systemic steroids.
- Patients taking immunosuppressives or biological therapies.
- Addiction to alcohol and / or drugs.
- Known allergy to the studied medications.
Interventions
Mesalamine or 5-amino salicylic acid (5-ASA), plays a crucial role in the treatment of ulcerative colitis (UC). It is the first-line therapy for mild to moderate cases of UC and is considered a cornerstone in its management.
Rupatadine, a dual histamine H1 receptor and platelet-activating factor (PAF) receptor antagonist, has shown promising anti-inflammatory effects beyond its conventional use in allergic conditions
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07064707